Replies to post #71322 on DNAprint Genomics (DNAG)

[stockhlder101]

DNAPrint seems to express confidence in their future..
----
"The COMING months.."
And-----
"As far as the shareholder award at some future date, we will fix the total number of outstanding shares and make the calculations effective a certain date that will be publically announced."
And----
"As Richard has said in presentations, we are working toward a date for distribution and preparing the filing for the SEC review and comment."

I like what they are saying!!





From: dnap <[e-mail]>
To:
Subject: RE: Question on Bioserve's 600,000 samples.
Date: Wed, 10 Oct 2007 16:05:16 -0400

Hello XXX - I spoke with Richard but we are not at the stage where we can devulge this kind of information. We will be developing a sales and marketing plan over the coming months.

thanks

Louise

Investor Relations
DNAPrint genomics, Inc.
V 941-366-3400
[e-mail]

________________________________

From:
Sent: Wed 10/10/2007 9:14 AM
To: dnap
Subject: Question on Bioserve's 600,000 samples.



How long will it take to process all of these samples for Bioserve.
What revenue is DNAPrint expecting with this project in the future?
Thanks!


From: dnap <[e-mail]>
To:
Subject: RE: DNAPrint Sharecount.. Questions
Date: Tue, 2 Oct 2007 16:18:48 -0400

Hi XXX, sorry I haven't been around - been in and out of the office lately. I'm trying to get to as many of your questions as I can possible answer.

Per your questions below, we don't follow the share distribution that closely but we did retire some shares and re-issued others. This is probably something to do with shutting down conversions and the end of the quarter. The independent accountants follow all aspects of our business, including share distributions.

As far as the shareholder award at some future date, we will fix the total number of outstanding shares and make the calculations effective a certain date that will be publically announced. I can't comment any more as I am restricted from commenting by SEC rules and regulations. As Richard has said in presentations, we are working toward a date for distribution and preparing the filing for the SEC review and comment.

Thanks,

Louise


Investor Relations
DNAPrint genomics, Inc.
V 941-366-3400
[e-mail]